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Background: Only 25% of patients
with HER-2/neu-positive metastatic
breast tumors respond favorably to
trastuzamab (Herceptin) treatment.
We hypothesized that a high failure
rate of patients on trastuzamab could
result if some of the metastases were
HER-2 negative and these metastases
ultimately determine the course of the
disease. Methods: We used tissue mi-
croarrays (TMAs) containing four
samples each from 196 lymph node-
negative primary tumors, 196 lymph
node-positive primary tumors, and
three different lymph node metastases
from each lymph node-positive tumor
to estimate HER-2 gene amplification
by fluorescence in situ hybridization
(FISH) and Her-2 protein overexpres-
sion by immunohistochemistry (IHC).
Results: FISH and IHC analyses gave
the same result with respect to HER-2
status for 93.7% of the tissues con-
tained in the TMAs. Tissue samples
were, therefore, considered to be
HER-2 positive if they were positive for
either HER-2 DNA amplification or
Her-2 protein expression and HER-2
negative if both FISH and IHC gave a
negative result. The HER-2 status of
lymph node-positive primary tumors
was maintained in the majority of their
metastases. For HER-2-positive pri-
mary tumors, 77% (95% confidence in-
terval [CI] = 59% to 90%) had entirely
HER-2-positive metastases, 6.5% (95%
CI = 8% to 21%) had entirely HER-2-
negative metastases, and 16.3% (95%
CI = 5% to 34%) had a mixture of
HER-2-positive and HER-2-negative
metastases. For HER-2-negative pri-
mary tumors, 95% (95% CI = 88% to
98%) had metastases that were entirely
negative for HER-2. Conclusions: Our
data suggest that differences in HER-2
expression between primary tumors
and their lymph node metastases can-
not explain the high fraction of nonre-
sponders to trastuzamab therapy.
[J Natl Cancer Inst 2001;93:1141–6]
The HER-2/neu (also known as ERBB2)
proto-oncogene, which encodes a trans-
membrane growth factor receptor with
tyrosine kinase activity, has become an
important subject for human cancer re-
search during the last decade. The impact
of HER-2 amplification and expression
on prognosis (1–12) and on the response
to cytotoxic (4,13–18) and hormonal
(15,19–22) therapies in breast cancer
patients have been studied intensively.
Studies of HER-2 represent a paradigm
of how genetic findings have led to the
development of a gene-specific therapy:
In September 1998, the U.S. Food and
Drug Administration approved trastuzamab
(Herceptin), a recombinant monoclonal
antibody targeting Her-2, for the treat-
ment of metastatic breast cancer. Al-
though trastuzumab binds to the Her-2
receptor with high affinity, the mecha-
nism of action by which it causes tumor
reduction is not understood. Despite the
theoretic benefits of such a targeted treat-
ment, not all patients respond favorably to
trastuzamab treatment in practice. Among
the patients with HER-2-positive meta-
static breast cancer that is resistant to con-
ventional cytotoxic treatment, only about
25% benefit from trastuzamab given in
combination with cisplatin (23). The ge-
netic features that distinguish the HER-2-
positive breast cancers that respond to
trastuzamab from those that do not remain
unclear. However, it is possible that the
extent of HER-2 amplification and/or
overexpression in the primary tumor dif-
fers from that in the metastases. The
HER-2 status of the primary tumor, which
is removed from the patient, determines
whether or not trastuzamab treatment is
prescribed. But trastuzamab works by tar-
geting the metastases that remain in the
patient. If at least some of the multiple
metastases of an HER-2-positive primary
breast tumor did not express HER-2,
trastuzamab treatment would most likely
not affect the course of the disease. A
comprehensive, large-scale study compar-
ing HER-2 gene copy numbers and pro-
tein expression in primary tumors and in
multiple different metastases derived
from them has not been performed. To
gain insight into the patterns of HER-2
expression in primary and metastatic
breast cancers, we utilized our recently
developed tissue microarray (TMA) tech-
nique (24) to study HER-2 gene amplifi-
cation and protein overexpression in the
primary tumor and in three different me-
tastases of each of 196 highly metastatic
breast carcinomas.
PATIENTS AND METHODS
Patients
We randomly selected two different groups of
196 tumors each from a consecutive series of more
than 3000 breast cancers that were routinely exam-
ined in the Institute of Pathology at the Kantonsspi-
tal Basel (Switzerland) from 1985 through 1995.
Each primary tumor came from a different patient.
The first group of tumors consisted of 196 lymph
node-negative tumors, which included 133 ductal
carcinomas, 37 lobular carcinomas, and 26 tumors
of other histologic subtypes. Among this group of
tumors, 10% were pT1, 74% were pT2, 9% were
pT3, and 7% were pT4 carcinomas according to
classification by the International Union Against
Cancer (25). The second set of tumors consisted of
196 primary breast cancers that had three or more
positive axillary lymph nodes with metastases larger
than 0.5 cm in diameter and for which tissue blocks
were available from both the primary cancer and
the axillary lymph node metastases. This group
of lymph node-positive primary tumors included
145 ductal carcinomas, 25 lobular carcinomas, and
26 tumors of other histologic subtypes. Among this
group of tumors, 14% were pT1, 45% were pT2,
16% were pT3, and 25% were pT4 cancers. We
could not determine the tumor stage from the pa-
thology reports for two patients whose tumors were
part of this group.
TMA Construction
Tissue samples were fixed in buffered 4% forma-
lin, embedded in paraffin, and used to construct
TMAs as described previously (24). Briefly, hema-
toxylin–eosin-stained sections were made from each
selected primary tumor block (donor blocks) to de-
fine representative tumor regions. Tissue cylinders
(0.6 mm in diameter) were then punched from that
region of the donor block with the use of a custom-
made precision instrument (Beecher Instruments,
Silver Spring, MD).
Tissues cylinders from the 196 lymph node-
negative primary tumors, the 196 lymph node-
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positive primary tumors, and three different lymph
node metastases of each of the lymph node-positive
primary tumors (3 × 196 metastases) were distrib-
uted among three 25-mm × 35-mm paraffin blocks
to produce the TMA blocks used for our study. Two
of the blocks in each set contained 400 samples
each, and one block contained 180 samples. One
complete set of TMA blocks containing a total
of 980 tissue samples stained with hematoxylin–
eosin is shown in Fig. 1, A; a single tissue spot
stained with hematoxylin–eosin-stained is shown in
Fig. 1, B.
We constructed four sets of complete TMA
blocks; each set contained tissue samples collected
from different representative regions of the donor
tissues. The resulting TMA blocks were cut into
3-mm sections that were transferred to glass slides
by use of the Paraffin Sectioning Aid System (In-
strumedics, Hackensack, NJ). A separate section
from each of the four complete sets of TMA blocks
was used for fluorescence in situ hybridization
(FISH) and immunohistochemical analysis.
Fluorescence In Situ Hybridization
Slides containing sections of TMA blocks were
treated before hybridization with a paraffin pretreat-
ment kit (Vysis Inc., Downers Grove, IL) according
to the manufacturer’s instructions. The sections
were air-dried and dehydrated by successive washes
in 70%, 85%, and 100% ethanol and then incubated
in 70% formamide and 2 × standard saline citrate
(SSC) (1.75% sodium chloride/0.89% sodium citrate
[pH 7]) for 5 minutes at 74 °C to denature the tumor
DNA. Slides were then incubated with a Spectrum-
Orange™-labeled HER-2 DNA probe and a Spec-
trumGreen™-labeled centromere 17 reference probe
(PathVision™; Vysis Inc.) in hybridization buffer
(2 g of dextran sulfate/10 mL of formamide in 2 mL
20 × SSC) overnight at 37 °C in a humidified cham-
ber. After hybridization, the slides were washed in
2 × SSC/0.3% Nonidet P-40, and the DNA was
counterstained with 0.2 M 4,6-diamidino-2-
phenylindole (DAPI) in an antifade solution
(Vectashield; Vector Laboratories, Inc., Burlingame
CA). We analyzed the slides by indirect immuno-
fluorescence microscopy by use of a Zeiss Axiophot
microscope equipped with Zeiss filtersets (Carl
Zeiss, Göttingen, Germany) for DAPI, fluorescein
isothiocyanate, and Texas Red (Carl Zeiss) under
100-fold magnification. In contrast to the manufac-
turer’s directions, we did not count the HER-2 and
centromere 17 signals in a defined number of cells
for each tumor in this study. Instead, we estimated
the mean number of HER-2 and centromere 17 sig-
nals for each tumor sample. In previous experi-
ments, we found that estimation of signals and sig-
nal counting gave identical results with respect to
HER-2 gene amplification (26). Our criteria for
HER-2 gene amplification were an HER-2 to cen-
tromere 17 signal ratio of at least three or tight
clusters of more than five HER-2 signals in more
than 10% of tumor cells in the tissue spot. These
criteria for HER-2 amplification were similar to
those used in previous studies (27,28) and resulted
in fewer borderline cases than the criterion (an HER-
2/centromere 17 signal ratio of at least two) recom-
mended by the manufacturer.
Immunohistochemistry
We analyzed Her-2 protein expression in the
TMAs by use of the HercepTest™ kit (DAKO
Diagnostics, Glostrup, Denmark) according to the
manufacturer’s instructions. Briefly, the deparaf-
finized tissue sections were first incubated in a 95 °C
waterbath for 40 minutes to induce epitope retrieval
and then at room temperature for 30 minutes with
the prediluted primary antibody to Her-2. Bound pri-
mary antibody was visualized by use of the dextran
polymer conjugated with horseradish peroxidase and
affinity-isolated goat anti-rabbit immunoglobins as
provided by the manufacturer. We included the posi-
tive and negative control cell lines supplied with the
HercepTest kit in each immunohistochemistry (IHC)
assay to ensure the validity of the staining. Stained
TMAs were analyzed by light microscopy by use of
a 10× objective. We scored immunohistochemical
staining according to the manufacturer’s instruc-
tions: Tissue samples were classified as positive if
they had a score of 2+ or 3+ and as negative if they
had a score of 0 or 1+.
Statistical Analysis
We calculated exact 95% confidence intervals
(CIs) for proportions based on a binominal probabil-
ity distribution to assess the accuracy of the esti-
mates of HER2 status in primary tumors and metas-
tases. Fisher’s exact test was used to compare the
proportions of HER-2-positive and HER-2-negative
samples in complete and incomplete datasets to as-
sess the influence of missing values.
RESULTS
We first determined whether FISH and
IHC gave the same result with respect to
HER-2 status. Because each of the four
TMAs contained a tissue sample from a
different area of each of the 980 tumor
samples, a total of 3920 different samples
were analyzed in this study. We could
interpret unambiguously the results of the
FISH or IHC analyses for 3727 (95.1%)
of these 3920 samples. Results of both the
FISH and IHC analyses were available for
2857 samples. When we compared the re-
sults of the two types of analyses for these
2857 samples, we found that 2677 sam-
ples (93.7%) gave the same result with
respect to HER-2 status for analyses per-
formed by FISH and by IHC and that
these samples showed an increase in the
frequency of HER-2 gene amplification
Fig. 1. Breast cancer tissue microarrays (TMAs). Panel A: one complete set of TMAs, stained with
hematoxylin–eosin, consisting of three paraffin blocks (25 × 30 mm) containing 400 (block 1), 400 (block
2), and 180 (block 3) breast cancer samples. Panel B: example of a single hematoxylin–eosin-stained tissue
spot. Panel C: fluorescence in situ hybridization (FISH) analysis of a tumor cell containing amplified HER-2
DNA with two centromere 17 signals (green) and a tight cluster containing more than five HER-2 signals
(red). Panel C: FISH analysis of tumor cells containing unamplified HER-2 DNA. Each cell has two
centromere 17 signals (green) and one or two HER-2 signals (red). The nuclear DNA (blue) in panels C
and D is stained with 4,6-diamidino-2-phenylindole.
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with increasing Her-2 protein expression
score (Fig. 2, A). We attributed about two
thirds of the uninterpretable results to
technical problems associated with the
TMAs; these included missing samples
(lost during sectioning of the arrays) and
tissue samples with low numbers of tumor
cells (28). Technical problems with FISH,
such as weak hybridization signals or ex-
cessive background, made the results of
other samples uninterpretable. Examples
of interpretable tumor tissue samples con-
taining amplified HER-2 DNA and non-
amplified HER-2 DNA are shown in Fig.
1, C and D, respectively. On the basis of
the strong agreement between FISH and
IHC data, we decided to classify a tumor
sample as HER-2 positive if at least one
of the two tests was interpretable and
gave a positive result (i.e., a score of 2+ or
3+ in the IHC assay; HER-2 gene ampli-
fication by FISH). All of the remaining
interpretable tissues that showed no am-
plification by FISH and an HER-2 score
of 0 or 1+ by IHC were considered to be
HER-2 negative.
We next investigated HER-2 status
among the four samples of each lymph
node-negative primary tumor and of each
lymph node-positive primary tumor and
of the three metastases corresponding to
each lymph node-positive primary tumor.
We included in this analysis only the 856
primary tumors and metastases for which
all four tissue samples gave an interpret-
able result (either by FISH or by IHC). As
shown in Fig. 2, B, for most of the tumors
analyzed, different samples from the same
tumor gave the same result with regard to
HER-2 status. Overall, among the 856 tis-
sues for which all samples were interpret-
able, only 23 (2.7%) samples differed be-
tween the four tissue samples with respect
to HER-2 status.
We then compared the HER-2 status
of the lymph node-positive primary tu-
mors with that of their metastases. This
analysis was restricted to the 125 lymph
node-positive tumors, for which 16 ar-
rayed tissue samples (four samples each
of the primary tumor and of three differ-
ent metastases) yielded interpretable re-
sults on HER-2 status. We categorized the
primary tumors into one of three groups
based on the HER-2 status of the four
tissue samples from each tumor; positive,
negative, or heterogeneous. Tumors were
considered to be positive if all four tissue
samples were HER-2 positive, negative
if all four tissue samples were HER-2
negative, and heterogeneous if the four
tissue samples yielded a mixture of HER-
2-positive and HER-2-negative results.
On the basis of these criteria, of the 125
lymph node-positive primary tumors, 31
(24.8%; 95% CI  18% to 33%) were
HER-2 positive, 91 (72.8%; 95% CI 
64% to 80%) were HER-2 negative, and
three (2.4%; 95% CI 0.5% to 7%) were
heterogeneous for HER-2.
Similarly, for each lymph node-posi-
tive primary tumor, we categorized the
HER-2 status of each of the associated
metastases into one of four groups based
on the HER-2 status of the four tissue
samples from each metastasis; positive,
negative, completely discordant, or par-
tially discordant. The lymph node metas-
tases for a given primary lymph node-
positive tumor were considered to be
positive if all four tissue samples of each
of the three metastases were HER-2 posi-
tive, negative if all four tissue samples of
each of three metastases were HER-2
negative, completely discordant if all four
tissue samples of one or two metastases
were either HER-2 positive or HER-2
negative, and partially discordant if at
least one metastasis had both HER-2-
positive and HER-2-negative tissue sam-
ples.
The HER-2 status of the lymph node-
positive primary tumors was maintained
in the majority of their metastases (Fig.
3). For example, 95% (95% CI 88% to
98%) of the HER-2-negative primary tu-
mors had metastases that were entirely
negative for HER-2, whereas 77% (95%
CI 59% to 90%) of the HER-2-positive
primary tumors had metastases that were
entirely positive for HER-2. However, a
small number of both HER-2-positive and
HER-2-negative primary tumors pro-
duced metastases whose HER-2 status
differed from that of the primary tumor.
Fig. 2. HER-2 status in
different tissue samples
from each tumor. Panel
A : c o m p a r i s o n o f
HER-2 expression de-
termined by immunohis-
tochemistry (IHC) and
HER-2 amplification
determined by fluores-
cence in situ hybridiza-
tion (FISH). Only tissue
samples from the four
replicate arrays that had
results for both IHC and
FISH (n 2857) are in-
cluded. Bars represent
the fraction (%) of tis-
sues with negative (IHC
score of 0), weak (IHC
score of 1+), moderate
(IHC score of 2+), and
strong (IHC score of 3+)
Her-2 protein expres-
sion that showed HER-2
amplification. Panel B:
heterogeneity of HER-2
status among the four
tissue samples from
each tumor. pTN0 
primary lymph node-
negative breast cancer;
pTN+ primary lymph
node-positive breast
cancer; and LN1–LN3
 three sets of lymph
node metastases of the
pTN+ primary tumors.
Only tumors with interpretable immunohistochemical and/or FISH results in all four tissue samples are
included. Black area = percentage of tumors that were positive for HER-2 (HER-2 gene amplification and/or
HercepTest™ score of 2+ or 3+) in all four tissue samples; white area  percentage of tumors that were
negative for HER-2 (no HER-2 gene amplification and score 0 or 1+) in all four tissue samples; and gray
area  percentage of tumors for which one or two of the four tissue samples had an HER-2 status that
differed from that of the remaining samples.
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For example, two (6.5%) of the 31 HER-
2-positive primary tumors had metastases
that were entirely negative for HER-2,
and two (2.2%) of the 91 HER-2-negative
primary tumors had metastases that were
entirely HER-2 positive. As expected, the
three primary tumors with a heteroge-
neous HER-2 status produced metastases
that varied greatly in HER-2 status. One
of the heterogeneous primary tumors pro-
duced three metastases that were entirely
HER-2 positive, one produced three me-
tastases that were entirely HER-2 nega-
tive, and one produced metastases that
contained both HER-2-positive and HER-
2-negative tissue samples.
Of the 125 lymph node-positive pri-
mary tumors analyzed, nine (7.2%; 95%
CI  3% to 13%) produced metastases
with partially or completely discordant
HER-2 status. Only two of these primary
tumors (both with amplified HER-2 DNA
as determined by FISH) exhibited a com-
plete discordance of HER-2 status (i.e., all
samples of at least one of the metastases
were HER-2 negative). The remaining
seven primary tumors exhibited partial
discordance of HER-2 status (i.e., at least
one of their metastases had both HER-2-
positive and HER-2-negative samples).
To provide a statistical basis for these
results and to determine the effects of in-
complete datasets on these findings, we
calculated exact 95% CIs for proportions
to assess the accuracy of our estimates of
HER-2 status in the 125 lymph node-
positive primary tumors and their metas-
tases. To exclude the possibility that the
HER-2 results for the tumors for which
not all samples from the four replicate ar-
rays were interpretable might bias these
estimates, we also performed a separate
calculation for the 68 primary lymph
node-positive tumors and their metastases
that lacked one or more results for FISH
and/or IHC. There was no statistically sig-
nificant difference (P  .7866) in the
proportions of HER-2-positive and HER-
2-negative tissue samples between com-
plete and incomplete datasets (data not
shown).
DISCUSSION
HER-2 is the most frequently overex-
pressed oncogene in breast cancer: It
is detected in approximately 20%–30%
of ductal carcinomas. Overexpression of
HER-2 is strongly associated with ampli-
fication of the HER-2 gene. Although
trastuzamab treatment of breast cancer is
restricted to patients with metastatic pri-
mary tumors that express high amounts of
HER-2, this treatment has a high failure
rate. We studied HER-2 gene amplifica-
tion and overexpression in primary tu-
mors and their lymph node metastases to
evaluate whether differences in their
HER-2 status might account for the fail-
ure of trastuzamab treatment. Our results
demonstrate that the HER-2 status within
individual breast tumors is fairly homo-
geneous, as is the HER-2 status of pri-
mary tumors and their metastases. Fewer
than 5% of primary tumors or their me-
tastases showed heterogeneity in HER-2
status.
TMAs containing multiple samples
from individual tumor specimens are an
ideal tool for a systematic analysis and
quantification of tissue heterogeneity. The
more heterogeneous the distribution of a
particular tissue characteristic, such as
HER-2 expression, in a tumor, the less
likely it is that the alteration will be de-
tected in all arrayed samples of that tu-
mor. Our observation of little heterogene-
ity of HER-2 expression in breast cancer
is consistent with previous reports de-
scribing homogeneous HER-2 expression
as assayed by IHC across breast cancer
specimens (29,30). Further evidence
against significant heterogeneity of
HER-2 alterations in primary breast can-
cer is provided by previous studies report-
ing a high concordance of HER-2 ampli-
fication/overexpression between needle
biopsy specimens and resected specimens
(26,31). More than 95% of our patients
had a homogeneous HER-2 status in their
primary tumor and identical findings in
all their metastases. These findings, to-
gether with the known high frequency of
HER-2 overexpression in ductal carci-
noma in situ (32) and the lack of a sig-
nificant increase in HER-2 amplification
or overexpression with tumor stage (33),
suggest that the molecular events that
Fig. 3. HER-2 results
for a set of 125 primary
metastatic breast tu-
mors (pTN+) and 375
(3 × 125) corresponding
lymph node metastases.
Only tumors for which
there were 16 interpret-
able samples per patient
(four tissue samples of
each primary tumor and
four tissue samples of
each of three primary tu-
mor-associated metasta-
ses) are included. The
column (left) shows the
fractions of lymph node-
positive primary tumors
with a positive (all four
samples HER-2 posi-
tive), negative (all four
samples HER-2 nega-
tive), and heterogeneous
(a mixture of HER-2-
positive and HER-2-
negative tissue samples)
H E R - 2 s t a t u s . P i e
charts show the HER-2
status of the three lymph
node metastases associ-
ated with the primary
lymph node-positive
tumors with a given
HER-2 status. Negative
 all four tissue sam-
ples of each of the three
primary tumor-associ-
ated metastases were
HER-2 negative; positive all four tissue samples of each of the three primary tumor-associated metastases
were HER-2 positive; complete discordance  the HER-2 status of all tissue samples of one metastasis
differed from the HER-2 status of the remaining metastases; and partial discordance  at least one of the
metastases had both positive and negative samples for HER-2.
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cause alterations in HER-2 expression oc-
cur early in tumorigenesis in a subset of
breast cancers. Regardless of the mecha-
nism responsible, cells that overexpress
HER-2 may have a strong growth advan-
tage resulting in the rapid replacement
of tumor cells that do not overexpress
HER-2.
We found evidence for tissue hetero-
geneity with respect to the proportions of
HER-2-positive and HER-2-negative
cells detectable by IHC or FISH in a small
number of tumors. Among the 91 HER-
2-negative primary tumors, five (5.5%)
had HER-2-positive metastases. It is un-
likely that de novo amplification or over-
expression of the HER-2 gene occurred in
these metastases because, in some of the
arrayed samples, all three metastases of
the HER-2-negative primary tumors were
positive for HER-2. In addition, a small
group of heterogeneous primary tumors
produced HER-2-positive metastases.
These observations suggest that a positive
HER-2 status in the primary tumor does
not directly influence the metastatic capa-
bilities of tumor cells. In heterogeneous
primary tumors having both HER-2-
positive and HER-2-negative lymph node
metastases, it can be assumed that the
molecular event(s) required for metastasis
occurred before HER-2 amplification and
that separate HER-2-positive and HER-2-
negative tumor cells have established the
metastases.
The analysis of more than 2500 tumor
samples by both IHC and FISH allowed a
comprehensive comparison of these two
methods of determining HER-2 status.
We observed a high concordance (93.7%)
between the FISH and the IHC results,
which has also been observed in other
studies (34,35). We observed a high per-
centage (66%) of HER-2-amplified tu-
mors with a Her-2 protein expression
score of 1+. This was unexpected be-
cause, in most previous studies, the per-
centage of HER-2-amplified tumors with
HER-2 expression scores of 1+ was less
than 10% (29,36,37).
The TMA technique has a number of
distinct advantages over traditional meth-
ods using large sections, including an im-
proved standardization, capacity, and
speed of analysis as well as the potential
of automatization of both array construc-
tion and analysis. By default, the analysis
of all tumors of one study under identical
conditions in a single experiment opti-
mizes experimental standardization.
While tumor blocks containing precious
material are usually exhausted after 200–
300 sections, the tissue-array technique
allows the construction of hundreds of
replica arrays from one set of tumors and
thus tens of thousands in situ analyses.
It is likely that the speed and, more im-
portant, the objectivity of immunohisto-
chemical analyses will be substantially
improved by automated analysis. Further
optimizations of the technology, includ-
ing automation of array analysis, automa-
tion of array production, and an increased
availability of tissue arrays, will make this
approach a standard tool for tissue-based
research.
Our data suggest that the high rate of
nonresponse to trastuzamab therapy can-
not be explained by heterogeneity with
respect to HER-2 status between primary
tumors and their lymph node metastases.
Although we cannot entirely exclude the
possibility that very small subpopulations
of HER-2-negative cells were present
in the HER-2-positive tumors analyzed in
our study, we think that it is unlikely that
such cells could cause a total lack of re-
sponse to trastuzamab therapy in patients.
An initial treatment effect on the much
larger population of HER-2-positive tu-
mor cells would result in a significant
tumor reduction that would clearly lead to
a clinically detectable remission. Future
studies will be needed to identify the ge-
netic or epigenetic differences that may
distinguish trastuzamab-responsive from
nonresponsive HER-2-positive tumor
cells.
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